[Ovid] Adjuvant therapy in renal cell carcinoma. Does the end justify the means? A reflection on KEYNOTE-564 and LITESPARK-022 benefits and harms

fercuneo Post time 2026-9-7 22:58:49 | Show all posts |Read mode
This post will be closed automatically in 2026-09-10 22:58
Reward10points

journal:Journal of Urology

Authors:Daniel A. González-Padilla; José Daniel Subiela; Dries Develtere; Felipe Villacampa-Aubá

Published date:--

DOI:10.1097/ju.0000000000005283

PDF link:http://www.auajournals.org/doi/pdf/10.1097/JU.0000000000005283

Article link:https://doi.org/10.1097/ju.0000000000005283

Article Source:Ovid Technologies (Wolters Kluwer Health)


Remark:

Best Answer

Please approve

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
Logan22 Post time 2026-9-7 22:58:50 | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Senior Member
  • post

  • reply

  • points

    29050


Return to the list